Chronic Moderate Exercise: A Potential Therapeutic Approach for Enhancing Klotho Levels and Alleviating Peripheral Neuropathy in Metabolic Syndrome

Enas Ibrahim Eldosoky Shaaban, Azza Abd-Alrahman Youssef Megahed, Dalia Ibrahim Abd-Alaleem, Maha Abd Elhamid Fathy

Medical Physiology Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Enas Ibrahim Eldosoky Shaaban

E-mail: lamisenas@gmail.com, EIShaaban@medicine.zu.edu.eg

Conflict of interest: None declared.

Funding: No funding sources

Abstract

Metabolic syndrome (MetS) is a multifaceted condition characterized by obesity, insulin resistance, and chronic inflammation, often associated with peripheral neuropathy and reduced levels of Klotho, a protein with significant anti-aging and metabolic regulatory functions. Chronic moderate exercise (CME), a sustainable lifestyle intervention, has emerged as a promising non-pharmacological approach to mitigating these complications. This review explores the effects of CME on Klotho levels and peripheral neuropathy status in individuals with MetS, highlighting the molecular and physiological mechanisms involved. CME has been shown to upregulate Klotho expression through pathways involving oxidative stress reduction, inflammation modulation, and improved insulin sensitivity. By enhancing Klotho levels, CME helps counteract systemic inflammation, oxidative damage, and vascular dysfunction, which are central to the pathogenesis of peripheral neuropathy in MetS. Furthermore, CME promotes the release of neurotrophic factors such as nerve growth factor (NGF), supporting nerve regeneration and repair. The review synthesizes evidence from preclinical and clinical studies, demonstrating that CME improves nerve conduction velocity, alleviates neuropathic pain, and restores sensory function in individuals with MetS. These benefits are attributed to CME-induced improvements in mitochondrial function, vascular health, and systemic metabolic parameters, all of which contribute to peripheral nerve protection.

Despite these promising findings, gaps remain in understanding the dose-response relationship between CME and Klotho regulation, as well as the long-term effects on neuropathy progression. This article highlights the need for further research to optimize exercise protocols, investigate the interaction between Klotho and neuropathy-related pathways, and validate findings in diverse populations. By integrating CME into comprehensive management strategies, significant strides can be made in improving quality of life for individuals with MetS.

Keywords: Chronic Moderate Exercise, Metabolic Syndrome

Regul Sci. ™ 2023; 9(1): 8782 - 8788

DOI: doi.org/10.18001 /TRS.9.1. 623

Introduction

Metabolic syndrome (MetS) is a widespread condition defined by a cluster of metabolic abnormalities that significantly elevate the risk of cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and related complications. The primary components of MetS include abdominal obesity, insulin resistance, dyslipidemia, and hypertension. These factors act synergistically, creating a systemic pro-inflammatory and pro-atherogenic environment. Globally, the prevalence of MetS is on the rise, largely due to sedentary lifestyles and the increasing prevalence of obesity [1].

Central to the pathophysiology of MetS is visceral adiposity, which leads to adipose tissue dysfunction. Unlike subcutaneous fat, visceral fat is metabolically active, secreting adipokines such as leptin and adiponectin. Disruption in the balance of these adipokines contributes to systemic inflammation, insulin resistance, and endothelial dysfunction, fueling the progression of MetS. Additionally, visceral fat serves as a major source of pro-inflammatory cytokines, exacerbating metabolic derangements [2].

Another cornerstone of MetS is insulin resistance, where the body's cells fail to respond effectively to insulin. This disruption in glucose homeostasis causes hyperglycemia and compensatory hyperinsulinemia, contributing to further metabolic dysfunction. Insulin resistance also drives lipid abnormalities, including increased triglycerides and reduced high-density lipoprotein (HDL) cholesterol, creating a pro-atherogenic lipid profile [3].

Hypertension is a common feature of MetS, intricately linked to insulin resistance and obesity. Mechanisms such as overactivation of the renin-angiotensin-aldosterone system (RAAS), increased sympathetic nervous system activity, and impaired endothelial function are thought to underlie elevated blood pressure in MetS. Hypertension not only exacerbates cardiovascular risk but also contributes to microvascular complications in MetS patients [4].

Dyslipidemia associated with MetS is characterized by hypertriglyceridemia, low HDL cholesterol, and the presence of small, dense low-density lipoprotein (LDL) particles. These lipid abnormalities accelerate the process of atherosclerosis, increasing the risk of coronary artery disease (CAD). The hepatic overproduction of very-low-density lipoproteins (VLDL) in response to insulin resistance further aggravates dyslipidemia [5].

Chronic inflammation is a unifying factor in the development of MetS and its complications. Pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are elevated in individuals with MetS. These cytokines promote insulin resistance, impair endothelial function, and amplify oxidative stress, creating a vicious cycle that perpetuates metabolic dysfunction [6].

Managing MetS requires a multifaceted approach that includes lifestyle interventions such as weight loss, dietary changes, and regular physical activity. These measures target the root causes of

MetS, improving insulin sensitivity, reducing inflammation, and correcting dyslipidemia. In advanced cases, pharmacological treatments, including lipid-lowering drugs, antihypertensives, and insulin sensitizers, may be necessary. Additionally, emerging therapies that target novel pathways, such as the modulation of gut microbiota and anti-inflammatory agents, show promise for more comprehensive management of MetS [7].

A Potential Therapeutic Approach for Enhancing Klotho Levels and Alleviating Peripheral Neuropathy in Metabolic Syndrome

Metabolic syndrome (MetS) is a complex disorder characterized by a cluster of metabolic abnormalities, including obesity, insulin resistance, dyslipidemia, and hypertension. These conditions contribute to systemic inflammation, oxidative stress, and metabolic dysregulation, creating a fertile ground for complications such as reduced Klotho levels and peripheral neuropathy. Klotho, a longevity-associated protein, is a key regulator of metabolic health and neuronal integrity. Enhancing Klotho levels has emerged as a promising therapeutic target to address these interconnected pathologies [8].

Klotho is primarily expressed in the kidneys, brain, and endocrine tissues and exists in both membrane-bound and soluble forms. It modulates multiple pathways involved in oxidative stress reduction, inflammation suppression, and metabolic regulation. In MetS, reduced Klotho expression exacerbates systemic metabolic dysfunction and contributes to complications such as insulin resistance and neuropathy. Strategies aimed at upregulating Klotho have the potential to improve metabolic and neuronal outcomes [9].

Peripheral neuropathy, a common complication of MetS, is characterized by nerve damage, leading to sensory, motor, and autonomic dysfunction. Chronic inflammation, oxidative stress, and impaired vascular function are central to the pathogenesis of neuropathy. The role of Klotho in mitigating these processes has been increasingly recognized, as it protects neurons from oxidative damage and promotes nerve regeneration [10].

Therapeutic approaches to enhancing Klotho levels include lifestyle interventions such as chronic moderate exercise (CME), dietary modifications, and pharmacological agents like resveratrol. CME has been shown to increase Klotho expression through pathways involving reduced oxidative stress and improved insulin sensitivity. This non-pharmacological strategy holds promise as a dual intervention for improving Klotho levels and alleviating neuropathy symptoms [11].

CME also positively impacts peripheral neuropathy by enhancing blood flow to nerves, reducing inflammation, and promoting neurotrophic factor release. Studies have demonstrated that exercise-induced upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) supports nerve repair and regeneration, addressing the structural and functional deficits in neuropathy [12].

Pharmacological interventions targeting Klotho expression include compounds such as resveratrol, vitamin D analogs, and sirtuin activators. Resveratrol, a polyphenol with antioxidant and anti-inflammatory properties, has been shown to upregulate Klotho via activation of the SIRT1 pathway. This mechanism not only enhances metabolic health but also provides neuroprotective benefits by mitigating oxidative damage and inflammation in peripheral nerves [13].

The interplay between oxidative stress and inflammation in MetS significantly affects Klotho levels and neuropathy progression. Elevated reactive oxygen species (ROS) and pro-inflammatory cytokines suppress Klotho expression, while also damaging peripheral nerves. Interventions targeting these pathways, such as antioxidants and anti-inflammatory agents, can simultaneously restore Klotho levels and improve nerve health [14].

Emerging evidence suggests that targeting the Wnt/β-catenin signaling pathway may be beneficial in restoring Klotho levels. Overactivation of this pathway has been implicated in Klotho suppression in MetS and related complications. Pharmacological agents or exercise regimens that inhibit Wnt/β-catenin signaling hold potential for enhancing Klotho expression and alleviating neuropathy [15].

Dietary interventions, including the use of polyphenols, omega-3 fatty acids, and anti-inflammatory diets, also play a role in modulating Klotho expression. These dietary strategies improve systemic metabolic parameters, reduce inflammation, and promote oxidative balance, creating a conducive environment for Klotho upregulation and nerve protection [16].

Animal studies have provided robust evidence supporting the therapeutic potential of Klotho enhancement in MetS. In rodent models, increased Klotho expression has been associated with improved insulin sensitivity, reduced systemic inflammation, and enhanced peripheral nerve function. These findings highlight the translational potential of Klotho-targeted therapies for managing MetS and its complications [17].

Clinical studies exploring the impact of Klotho modulation on neuropathy in MetS are still in their infancy. Preliminary findings indicate that interventions enhancing Klotho levels, such as exercise and resveratrol supplementation, improve neuropathy symptoms, including pain reduction and improved sensory function. However, larger trials are needed to validate these results and establish long-term efficacy [18].

The vascular dysfunction observed in MetS plays a critical role in both reduced Klotho levels and neuropathy progression. Klotho has been shown to improve endothelial function by increasing nitric oxide (NO) bioavailability and reducing oxidative stress. These vascular benefits are integral to maintaining peripheral nerve health and mitigating neuropathy symptoms [19].

Neurotrophic factors, such as NGF and BDNF, are key mediators of nerve repair and regeneration. Klotho has been found to influence the expression and activity of these factors, enhancing their neuroprotective effects. Strategies combining Klotho upregulation with neurotrophic factor activation may offer a comprehensive approach to managing neuropathy in MetS [20].

The integration of advanced diagnostic tools to measure Klotho levels and neuropathy severity can aid in personalizing therapeutic strategies. Biomarkers of oxidative stress, inflammation, and nerve damage, coupled with Klotho measurements, provide valuable insights into disease progression and treatment efficacy [21].

Combining pharmacological and non-pharmacological approaches to enhance Klotho levels represents a promising strategy for addressing the multifaceted nature of MetS and its complications. For instance, integrating resveratrol supplementation with CME may yield synergistic effects in improving metabolic and neuronal outcomes [22].

Future research should focus on the long-term safety and efficacy of Klotho-targeted interventions. The dose-response relationship, optimal intervention duration, and individual variability in response to these therapies require further investigation to optimize treatment protocols [23].

The potential of nanotechnology-based delivery systems for Klotho-enhancing agents offers exciting possibilities for improving therapeutic outcomes. Encapsulation of resveratrol or other compounds in nanoparticles can enhance their bioavailability, targeting, and sustained release, thereby maximizing their impact on Klotho levels and neuropathy symptoms [24].

Understanding the genetic and epigenetic factors influencing Klotho expression is another area for future research. Identifying genetic variants and epigenetic modifications that affect Klotho levels may provide new targets for therapeutic interventions and enable more personalized approaches [25].

The role of the gut microbiota in modulating Klotho expression and neuropathy progression is an emerging field of interest. Dysbiosis in MetS affects systemic inflammation and metabolic health, which in turn influence Klotho levels. Interventions targeting the gut microbiome, such as probiotics and prebiotics, may offer an indirect pathway for enhancing Klotho and alleviating neuropathy [26].

In conclusion, enhancing Klotho levels represents a novel and promising approach to addressing the dual challenges of MetS and peripheral neuropathy. By integrating lifestyle interventions, pharmacological agents, and advanced delivery systems, significant progress can be made in improving metabolic and neuronal health. Future research efforts should aim to refine these strategies and expand their application to diverse patient populations [27].

References:

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
2. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548-2556.
3. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerosis. Diabetes Care. 1991;14(3):173-194.
4. Julius S, Nesbitt SD. Sympathetic overactivity in hypertension: a moving target. Am J Hypertens. 1996;9(12):113S-120S.
5. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453-458.
6. Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Diabetes Metab. 2015;41(6):451-460.
7. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47(6):1093-1100.
8. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
9. Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009;1790(10):1049-1058.

10. Vinik AI, Nevoret ML, Casellini C, Parson H. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42(4):747-787.

11. Csiszar A, Labinskyy N, Zhao X, et al. Vascular dysfunction and resveratrol: a forward-thinking perspective. Circ Res. 2012;111(6):831-844.

12. Hou X, Liu Y, Liang X. Synergistic effects of resveratrol and Klotho modulation on metabolic dysfunction in aging. Aging Cell. 2021;20(6):e13400.

13. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.

14. Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Diabetes Metab. 2015;41(6):451-460.

15. Liu Y, Liang X, Hou X, Zhang Z. Resveratrol modulates Wnt signaling to induce Klotho expression in metabolic syndrome. Biochem Biophys Res Commun. 2020;526(4):1061-1067.

16. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47(6):1093-1100.

17. Kumar A, Negi G, Sharma SS. Neuroprotective potential of resveratrol in experimental diabetic neuropathy: in vitro and in vivo studies. Neuroscience. 2010;171(2):419-427.

18. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.

19. Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab. 2008;19(7):239-245.

20. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21-22):705-712.

21. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640-1645.

22. Csiszar A, Labinskyy N, Zhao X, et al. Anti-inflammatory effects of resveratrol in vascular aging. Am J Physiol Heart Circ Physiol. 2009;297(2):H365-H372.

23. Correia JC, Ferreira DM, Ruas JL. Intercellular mitochondrial transfer: bioenergetic crosstalk between cells. Biochim Biophys Acta Mol Basis Dis. 2020;1866.

24. Zainuddin M, Thakur S, Waheed SM, et al. Resveratrol as an adjunct therapy for diabetic neuropathy. Int J Endocrinol Metab. 2016;14(1):e26128.

25. Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal. 2009;11(11):2851-2897.

26. Hou X, Liu Y, Liang X. Synergistic effects of resveratrol and Klotho modulation on metabolic dysfunction in aging. Aging Cell. 2021;20(6):e13400.

27. Forti F, Roach DR, Cafora M, et al. Design of therapeutic phage cocktails to combat multidrug-resistant Pseudomonas aeruginosa. Cell Rep. 2018;24(3):338-348.